Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > REPL Replimune > Detailed Quotes

REPL Replimune

Watchlist
20.320
+0.340+1.70%
Close 12/02 16:00 ET
20.3200.0000.00%
Post Mkt Price 12/02 16:08 ET
High
20.400
Open
19.790
Turnover
8.08M
Low
19.610
Pre Close
19.980
Volume
403.03K
Market Cap
1.01B
P/E(TTM)
Loss
52wk High
30.890
Shares
49.74M
P/E(Static)
Loss
52wk Low
13.050
Float Cap
632.82M
Bid/Ask %
33.33%
Historical High
54.850
Shs Float
31.14M
Volume Ratio
1.33
Historical Low
8.580
Dividend TTM
--
Div Yield TTM
--
P/B
2.63
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.29%
Amplitude
3.95%
Avg Price
20.043
Lot Size
1
Float Cap
632.82M
Bid/Ask %
33.33%
Historical High
54.850
Shs Float
31.14M
Volume Ratio
1.33
Historical Low
8.580
Dividend TTM
--
P/B
2.63
Dividend LFY
--
Turnover Ratio
1.29%
Amplitude
3.95%
Avg Price
20.043
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO: Mr. Philip Astley-Sparke
Market: NASDAQ
Listing Date: 07/20/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist